Literature DB >> 8361323

Nicotine-induced analgesia in rats: the role of calcium and the diversity of responders and nonresponders.

R C Block1, C W Chin, W Wu, V K Zbuzek.   

Abstract

Following a single dose of nicotine, (NIC, 1 mg/kg s.c.), 60% of tested rats revealed significant antinociception as measured by the tail-flick (TF) test, and were classified as responders, with those in which TF latencies did not change, nonresponders. The following experiments were carried out one week later. In nonresponders, pretreatment with ethylenediaminetetraacetic acid (EDTA, 250 microM/kg s.c. four times every 15 min) followed by 1 mg NIC, produced significant analgesia in 50% of rats, to the same magnitude as did nicotine alone (1 mg) in responders. The other 50% of rats which failed to respond to EDTA pretreatment, all revealed similar analgesia following the higher dose of NIC (1.5 mg/kg s.c.), with similar side effects, as generally observed in responders. In responders, pretreatment with CaCl2 (1.5 mM/kg s.c.) completely abolished NIC (1 mg/kg s.c.)--induced analgesia in all rats. Our data provide stronger evidence and a further verification that EDTA potentiates, whereas CaCl2 completely abolishes, nicotine-induced analgesia in rats; supporting our hypothesis of the involvement of calcium ions in this effect.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8361323     DOI: 10.1016/0024-3205(93)90130-u

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  2 in total

Review 1.  Pain, nicotine, and smoking: research findings and mechanistic considerations.

Authors:  Joseph W Ditre; Thomas H Brandon; Emily L Zale; Mary M Meagher
Journal:  Psychol Bull       Date:  2011-11       Impact factor: 17.737

2.  Nicotine patch for the prevention of postoperative nausea and vomiting: a prospective randomised trial.

Authors:  Daniela Ionescu; Cristina Badescu; Iurie Acalovschi
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.